Get the Stockscreener App
4.15
3.49%
-0.15
Pre-market:
4.15
Savara Inc stock is traded at $4.15, with a volume of 1.30M.
It is down -3.49% in the last 24 hours and up +16.25% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$4.30
Open:
$4.29
24h Volume:
1.30M
Relative Volume:
0.88
Market Cap:
$717.27M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-12.58
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
-4.82%
1M Performance:
+16.25%
6M Performance:
+29.69%
1Y Performance:
+14.17%
1-Day Range:
$4.14
$4.40
1-Week Range:
$4.14
$4.505
52-Week Range:
$1.89
$4.505
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
4.15 | 743.26M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
2025-11-02 | Securities Fraud Class Action Filed Against Savara Inc. (SVRA)Levi & Korsinsky Reminds Investors of November 7, 2025 | NDAQ:SVRA | Press Release - Stockhouse
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit - PR Newswire
SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors ... - Bluefield Daily Telegraph
SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA - GlobeNewswire Inc.
Class Action Filed Against Savara Inc. (SVRA) Over Securities ViolationsContact Levi & Korsinsky Today - Stockhouse
Why Savara Inc. stock could outperform in 2025Trade Signal Summary & Low Risk Entry Point Guides - newser.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - Newsfile
How strong dollar benefits Savara Inc. (YB4P) stockStop Loss & Capital Efficient Trade Techniques - newser.com
Investors SueWallSt Over Savara Inc. Stock DropContact Levi & Korsinsky to Join - ACCESS Newswire
Savara completes $149.5 million public offering of common stock By Investing.com - Investing.com South Africa
Savara Closes $149.5 Million Public Offering - MarketScreener
Savara completes $149.5 million public offering of common stock - Investing.com
Savara (NASDAQ: SVRA) closes $149.5M offering priced at $4.20; option exercised - Stock Titan
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M - The Joplin Globe
Investors in Savara Inc. Should Contact Levi & Korsinsky Before November 7, 2025 to Discuss ... - Bluefield Daily Telegraph
Investors in Savara Inc. Should Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights – SVRA - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - Newsfile
Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025SVRA - Morningstar
SAVARA CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Savara Investors to ... - Bluefield Daily Telegraph
SAVARA CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, - GlobeNewswire
Is Savara Inc. (YB4P) stock in buy zone after pullbackStop Loss & Verified Short-Term Trading Plans - newser.com
Emerald Mutual Fund Advisers Trust Grows Position in Savara Inc. $SVRA - MarketBeat
Savara Inc. $SVRA Shares Purchased by Emerald Advisers LLC - MarketBeat
Pattern recognition hints at Savara Inc. upsideJuly 2025 Review & Risk Controlled Swing Trade Alerts - newser.com
Visual analytics tools that track Savara Inc. performanceJuly 2025 Macro Moves & Community Supported Trade Ideas - newser.com
Chart overlay techniques for tracking Savara Inc.Market Performance Recap & Stock Timing and Entry Methods - newser.com
RTW Biotech Opportunities says Savara announces $75 million funding agreement with co - MarketScreener
Latham & Watkins Advises RTW Investments in US$75 Million Royalty Funding Agreement With Savara - Latham & Watkins LLP
Will Savara Inc. (YB4P) stock boost dividends further2025 Support & Resistance & Daily Profit Focused Stock Screening - newser.com
What Does Wall Street Think About Savara Inc. (SVRA)? - MSN
SVRA FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Savara Inc. Investors to ... - Caledonian Record
SVRA FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, - GlobeNewswire
Applying sector rotation models to Savara Inc.Quarterly Portfolio Review & Risk Controlled Daily Plans - newser.com
Savara Announces $130 Million Public Offering - TipRanks
SVRA sets underwritten deal; 30-day option for 4,642,857 shares - Stock Titan
Savara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ... - Bluefield Daily Telegraph
Savara Inc. Sued for Securities Law Violations – Investors - GlobeNewswire
SVRA Deadline: Rosen Law Firm Urges Savara Inc. (NASDAQ: SVRA) Stockholders to Contact the Firm for Information About Their Rights - The AI Journal
Investors SueWallSt as Savara Inc. Faces Securities Fraud Allegations - Nasdaq
SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara - FinancialContent
Savara (NASDAQ:SVRA) Hits New 12-Month HighHere's Why - MarketBeat
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Quantum Corporation (QMCO), Tronox Holdings plc (TROX), Fly-E Group, Inc. (FLYE), and Savara Inc. (SVRA) - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRA - FinancialContent
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants - BioSpace
Savara (SVRA) Launches $130M Public Offering - GuruFocus
Savara (Nasdaq: SVRA) prices public offering: 23.8M shares, 7.14M pre-funded warrants - Stock Titan
Savara announces pricing of public offering at $4.20 per share - MarketScreener
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
Savara Inc. (NASDAQ: SVRA) Investor Alert: Deadline in Lawsuit on November 7, 2025 - openPR.com
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):